The project is an observational, prospective study. Its aim is to deepen our understanding of COVID-19 in older patients hospitalized and diagnosed with COVID-19. In particular, socioeconomic, diagnostic, biological, functional, therapy data will be collected at the patients' admission, during hospital stay, at the discharge and 1, 3, 6, 12 months after discharge. Results and findings will help support changes in clinical practice and decision making, with the aim to reduce the use of healthcare services and the healthcare expenditure.
Current knowledge about clinical and biological characteristics of COVID 19 among older people is very limited. A better comprehension of the clinical picture of older patients affected by COVID-19, (e.g. frailty, multimorbidity and polypharmacy patterns and functional performance) may significantly contribute to deepen our understanding of the clinical epidemiology knowledge of COVID-19 among hospitalized older people. Therefore, the ReportAge-COVID project aims to collect - using a minimum clinical and biological data set - a series of data and indicators on the conditions of elderly patients that are suspected of having a compatible clinical picture or were confirmed positive for COVID-19. Data will be collected at the patients' admission, during hospital stay, at discharge and 1, 3, 6, 12 months after discharge. In particular, the following specific pieces of information will be gathered: * routinely collected demographic, socioeconomic, clinical, biological and diagnostic data * frailty condition (by using the clinical frailty scale) * assessment of the functional capacities through ADL and IADL tests * health conditions; nutritional status; medications; treatments and procedures * biomarkers of aging including cytokines and anti-inflammatory molecules, previously identified in a focus group of experts Results and findings will help support changes in clinical practice and decision making, with the aim of reducing adverse outcomes, the worsening of health conditions in the elderly population, the use of healthcare services and, as a consequence, lower healthcare expenditure.
Study Type
OBSERVATIONAL
Enrollment
300
IRCCS INRCA Hospital
Ancona, Italy
RECRUITINGIRCCS INRCA Hospital
Casatenovo, Italy
RECRUITINGIRCCS INRCA Hospital
Fermo, Italy
RECRUITINGDescriptive-epidemiological analysis of health conditions
Collection of a set of data and indicators of the health conditions including personal data, clinical care, biological and diagnostic data, treatments/procedures and drug therapy
Time frame: Patients will be followed for the duration of hospital stay, an expected average of 20 days
Evaluation of frailty condition
Clinical Frailty Scale (CFS). The CFS divides patients into 9 classes from very fit (CFS=1) to terminally ill (CFS=9)
Time frame: At admission, at discharge, an expected average of 6 weeks and at 1, 3, 6, 12 months after discharge
Identification of biomarkers of inflammation
Analysis for IL6, IL-10, IL-2, IL-7, Alpha 1 Antitrypsin, IP10, MCP1, MIP1 alpha, TNF alpha, IFN alfa, IFN beta
Time frame: At admission, at discharge, an expected average of 6 weeks and at 1, 3, 6, 12 months after discharge
Assessment of functional capacity
Activity of Daily Living (ADL). A summary score ranges from 0 (low function, dependent) to 6 (high function, independent)
Time frame: At admission, at discharge, an expected average of 6 weeks and at 1, 3, 6, 12 months after discharge
Assessment of functional capacity
Activity of Instrumental of Daily Living (IADL). A summary score ranges from 0 (low function, dependent) to 8 (high function, independent)
Time frame: At admission, at discharge, an expected average of 6 weeks and at 1, 3, 6, 12 months after discharge
Evaluation of drug consumption
Drugs prior to admission, drugs administered during hospital stay, prescribed drugs at discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At admission, at discharge, an expected average of 6 weeks and at 1, 3, 6, 12 months after discharge
Evaluation of inflamma-miRs
Determination of miR-21, miR-146a, miR-155
Time frame: At admission, at discharge, an expected average of 6 weeks and at 1, 3, 6, 12 months after discharge